Haberman
Associates' publications are designed to help you understand and act on the
ever-changing science, technology, market, and strategic issues that affect the
life science industry. They also help you assess leading companies and their products
and technologies.
Our publications include in-depth
research and analysis in:
- Business strategy in
the pharmaceutical, biotechnology, and life science industry
- R&D
strategy
- Therapeutic area and pipeline strategy
- Technology assessment
We
apply similar types of research and analysis as in our publications to our consulting
engagements. However, our consulting engagements focus on your company's specific
issues, and on developing executable recommendations for action in collaboration
with you and your colleagues.
Organizations that publish
our books and reports include Cambridge
Healthtech Institute, Decision
Resources, Emirates Center
for Strategic Studies and Research (ECSSR) and Informa
Healthcare (the parent company of Scrip, Clinica, and PharmaProjects).
We also produce articles that have appeared in
such leading publications as Genetic Engineering News, Pharma DD, and PharmaWeek.
See our home page for examples.
For
information on our recent major publications, or to order them, please click on
the following links:
Animal
Models for Therapeutic Strategies. March 5, 2010. Allan B. Haberman, Ph.D.
Published by Cambridge Healthtech Institute.
Approaches
to Reducing Phase II Attrition. May 5, 2009. Allan B. Haberman, Ph.D.
Published by Cambridge Healthtech Institute.
Obesity
Drug Pipeline: Developing Therapies for a Complex Disease. September 18,
2008. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.
Blood-Brain
Barrier: Bridging Options for Drug Discovery and Development. May 9, 2008.
Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.
Diabetes
and Its Complications: Strategies to Advance Therapy and Optimize R&D.
April 27, 2007. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.
Emerging
Targets in Diseases with High Unmet Need: Alzheimer’s Disease, Lung Cancer,
Dyslipidemia, Type 2 Diabetes, and COPD. June 23, 2006. Allan B. Haberman,
Ph.D. Published by Cambridge Healthtech Institute.
Powering
Drug Discovery through Target Evaluation: Moving Beyond the Validation Paradigm.
August 18, 2005. Allan B. Haberman, Ph.D. Published by Cambridge Healthtech Institute.
“Biotechnology and the Future of the Pharmaceutical
Industry”. Allan B. Haberman, Ph.D. In Biotechnology and the Future
of Society: Challenges and Opportunities, Emirates Center for Strategic Studies
and Research (ESCCR), distributed by I.B. Tauris, June 2004.
Available
from the following sources:
Amazon.com
Barnes
& Noble
IB
Tauris
The
Emirates Center for Strategic Studies and Research
From
Data to Drugs: Strategies for Benefiting from New Drug Discovery Technologies.
July 1999. Allan B. Haberman, Ph.D., George R. Lenz, Ph.D., and Dennis E. Vaccaro,
Ph.D. Published by PJB Publications Ltd. (Scrip Reports).
